WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Chinese Vice Foreign Minister Ma Zhaoxu to attend G20 meeting: spokespersonPassion fruitFloods in Bangladesh affect over 1.3 million peopleChina, Africa push for healthier communitiesChina strongly condemns UK's suspension of extradition treaty with HKSARXi's Speech at Meeting of Central Commission for Public Sector Reform to Be PublishedChina to launch new research project on giant panda protectionFoldable phones surge in popularity amid stagnant marketFloods in Bangladesh affect over 1.3 million peopleWorld's longest undersea high